Is Suraksha Diagnostic Ltd (SURAKSHA) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Suraksha Diagnostic Ltd is a good quality company .

Is Suraksha Diagnostic Ltd (SURAKSHA) undervalued or overvalued?

The key valuation ratios of Suraksha Diagnostic Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Suraksha Diagnostic Ltd (SURAKSHA) share price return in the past 10 years?

Data is not available for this company

Is Suraksha Diagnostic Ltd (SURAKSHA) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Suraksha Diagnostic Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Suraksha Diagnostic Ltd (SURAKSHA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Suraksha Diagnostic Ltd (SURAKSHA) on 17-Apr-2026 16:59:59 at 16:59 is 282.05.

What is the P/E ratio of Suraksha Diagnostic?

The latest standalone P/E ratio of Suraksha Diagnostic as of 17-Apr-2026 is 41.54.

What is the P/B ratio of Suraksha Diagnostic Ltd (SURAKSHA)?

The latest standalone P/B ratio of Suraksha Diagnostic Ltd (SURAKSHA) as of 17-Apr-2026 is 6.06.

What is the 52-week high and low of Suraksha Diagnostic Ltd (SURAKSHA)?

The 52-week high of Suraksha Diagnostic Ltd (SURAKSHA) is Rs. 353.65 and the 52-week low is Rs. 224.10.

Suraksha Diagnostic Ltd (SURAKSHA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Suraksha Diagnostic Ltd (SURAKSHA)
Brand: Suraksha Diagnostic

Suraksha Diagnostic Ltd (SURAKSHA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Suraksha Diagnostic Ltd (SURAKSHA)

BSE: 544293 NSE: SURAKSHA

Key Metrics

Market Cap

₹1,469 Cr.

P/E Ratio

44.12

Price to Book (P/B)

6.18

Price to Sales (P/S)

4.99

EV/EBITDA

15.29

Return on Capital Employed (ROCE)

24.92%

Current Price

₹282.1

Return on Equity (ROE)

15.93%

Return on Assets (ROA)

9.78%

Operating Profit Margin

32.6%

Net Profit Margin

12.29%

Gross Profit Margin

30.4%

Book Value per Share

₹45.6

Sales Growth (YoY)

15.26%

Sales Growth (3 Years)

4.14%

Operating Profit Growth (1 Year)

15.59%

Operating Profit Growth (3 Years)

19.44%

Net Profit Growth (1 Year)

33.94%

52-Week Low / High

₹224 / 354

Net Profit Growth (3 Years)

9.26%

Dividend Yield

0.00%

Promoter Holding

49.10%

Pledged shares (%)
of Promoter's holding (%)

0.10%

Check Before You Invest

Q.1 Revenue growth of Suraksha Diagnostic Ltd?

Suraksha Diagnostic Ltd revenue growth is 15.3% for FY-2025 , which is above its 5 year CAGR of 9.9% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Suraksha Diagnostic Ltd?

Promoters hold 49.10% of the Suraksha Diagnostic Ltd, with 0.10% of their stake pledged, indicating low pledge risk.

Q.1 Revenue growth of Suraksha Diagnostic Ltd vs industry peers?

Suraksha Diagnostic Ltd revenue CAGR is 9.86% , compared to the industry median CAGR of 1.49% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Suraksha Diagnostic Ltd belong to?

Suraksha Diagnostic Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.

Q.1 Stock return of Suraksha Diagnostic Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -5.26% based on the current price.

DeciZen - make an informed investing decision on Suraksha Diagnostic

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation ⓘ

3. Price Trend

Suraksha Diagnostic stock performance

Key Ratios

Is Suraksha Diagnostic Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'12	Mar'13	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0%	0%	16.8%	16.1%	20.2%	6%	22.7%	9.6%	22.9%	24.9%	-
Value Creation Index ⓘ	NA	NA	0.2	0.2	0.4	-0.6	0.6	-0.3	0.6	0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	70.2	99.1	158	140	223	190	219	252	294
Sales YoY Gr.	-	NA	NA	41.2%	58.9%	-11.1%	59.4%	-14.8%	15%	15.3%	-
Adj EPS ⓘ	0	0	109.3	78.4	217.5	115.1	358.5	119.1	372.1	6.1	6.4
YoY Gr.	-	NA	NA	-28.3%	177.3%	-47.1%	211.4%	-66.8%	212.4%	-98.4%	-
BVPS (₹) ⓘ	0	0	695.5	775.2	1,712.5	1,805.7	2,149.9	2,236.2	2,576.5	40.5	45.6
Adj Net Profit ⓘ	0	0	7.5	5.4	15	7.9	24.7	8.2	25.7	32	33
Cash Flow from Ops. ⓘ	0	0	19.5	13.5	31.3	23.5	42.3	44.1	60.5	63.4	-
Debt/CF from Ops. ⓘ	0	0	1.5	3.1	0.4	0.7	0.5	0.3	0.1	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	9.9%	4.1%	15.3%
Adj EPS ⓘ	NA	-51%	-74.2%	-98.4%
BVPSⓘ	NA	-52.7%	-73.4%	-98.4%
Share Price	-	-	-	-5.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	15.3	10.4	17.2	6.5	17.9	5.4	15.3	16.4	14.8
Op. Profit Mgn % ⓘ	24.8	22.2	21.7	17.9	22.2	24.6	33.4	32.6	30.7
Net Profit Mgn % ⓘ	10.7	5.5	9.5	5.7	11.1	4.1	11.5	12.4	11.3
Debt to Equity ⓘ	0.6	0.8	0.1	0.1	0.1	0.1	0.1	0	-
Working Cap Days ⓘ	0	78	69	101	98	102	51	81	37
Cash Conv. Cycle ⓘ	0	-61	-30	-34	-13	-11	-13	-3	11

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	6.8	6.4
TTM Sales (₹ Cr.)	286	294
BVPS (₹) ⓘ	46.6	45.6
Reserves (₹ Cr.) ⓘ	232	227
P/BV ⓘ	6.06	6.18
PE ⓘ	41.54	44.12

From the Market
52 Week Low / High (₹)	224.10 / 353.65
All Time Low / High (₹)	224.10 / 449.00
Market Cap (₹ Cr.)	1,469
Equity (₹ Cr.)	10.4
Face Value (₹)	2
Industry PE ⓘ	86.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

0.10

* Pledged shares as % of Promoter's holding (%)

Valuation of Suraksha Diagnostic - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	70	99	157	140	223	190	219	252
Operating Expenses ⓘ +	53	77	123	117	175	146	148	170
Manufacturing Costs	5	6	13	5	38	47	49	61
Material Costs	9	14	21	26	60	27	27	30
Employee Cost	11	19	32	23	34	40	40	43
Other Costs ⓘ	27	39	58	63	43	32	31	36
Operating Profit ⓘ	17	22	34	23	48	44	71	82
Operating Profit Margin (%)	24.8%	22.2%	21.7%	16.2%	21.5%	23.4%	32.4%	32.5%
Other Income ⓘ +	1	1	2	1	2	4	4	4
Exceptional Items ⓘ	-0	0	0	0	0	0	-1	0
Interest ⓘ	1	4	2	2	2	10	10	9
Depreciation ⓘ	6	9	13	16	15	32	33	35
Profit Before Tax ⓘ	12	10	21	6	33	7	31	41
Tax ⓘ	4	5	6	-0	9	1	8	10
Profit After Tax	8	5	15	6	24	6	23	31
PAT Margin (%)	10.8%	5.6%	9.7%	4.6%	10.6%	3.2%	10.6%	12.3%
Adjusted EPS (₹)	109.6	79.7	220.5	93.3	344.2	94.4	342.4	6.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	49	55	120	126	150	156	179	211
Share Capital ⓘ	8	8	9	9	9	9	9	10
Reserves ⓘ	41	47	111	118	141	147	171	201
Debt +	23	33	8	16	19	8	5	3
Long Term Debt	19	29	8	10	12	8	5	3
Short Term Debt	4	4	0	7	7	0	0	0
Minority Interest	0	0	0	0	0	-0	-0	-1
Trade Payables	13	10	13	13	14	14	14	14
Others Liabilities ⓘ	19	28	32	16	18	103	101	107
Total Liabilities ⓘ	104	125	173	171	201	281	300	334
Fixed Assets
Net Fixed Assets ⓘ +	73	91	128	119	119	195	212	223
Gross Block	88	116	194	198	211	226	274	319
Accumulated Depreciation	15	24	67	79	92	31	62	96
CWIP ⓘ	0	0	0	0	1	2	1	11
Investments ⓘ	0	0	5	5	0	0	0	1
Inventories	2	4	5	4	6	6	7	8
Trade Receivables	3	5	6	6	8	5	9	14
Cash Equivalents	12	9	4	4	3	55	55	20
Others Assets ⓘ	13	16	24	32	64	18	17	57
Total Assets ⓘ	104	125	173	171	201	281	300	334

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	20	13	31	24	42	44	60	63
PBT ⓘ	12	10	21	6	33	7	31	41
Adjustment ⓘ	6	12	14	21	16	40	41	43
Changes in Working Capital ⓘ	4	-6	3	-3	-2	5	-4	-10
Tax Paid ⓘ	-3	-3	-7	-2	-4	-7	-9	-11
Cash Flow From Investing Activity ⓘ +	-42	-26	-20	-28	-44	-21	-35	-40
Capex	-40	-27	-16	-15	-19	-13	-43	-42
Net Investments	-4	-9	-3	-5	-27	-11	5	-1
Others ⓘ	2	10	-1	-7	2	3	3	4
Cash Flow From Financing Activity ⓘ +	17	10	-10	3	1	-24	-25	-24
Net Proceeds from Shares ⓘ	2	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-1	-4	-2	-2	-2	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0
Others ⓘ	16	14	-9	5	3	-23	-24	-23
Net Cash Flow ⓘ	-6	-3	1	-1	-0	-1	0	-0

Finance Ratio

PARTICULARS	Mar'15	Mar'16	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	15.76	10.84	17.73	5.3	17.4	4.01	13.93	15.93
ROCE (%)	16.8	16.12	20.19	6.04	22.65	9.62	22.94	24.92
Asset Turnover Ratio	0.68	0.87	1.06	0.81	1.2	0.79	0.75	0.8
PAT to CFO Conversion(x)	2.5	2.6	2.07	4	1.75	7.33	2.61	2.03
Working Capital Days
Receivable Days	14	13	12	16	11	12	11	16
Inventory Days	11	11	11	13	9	12	11	11
Payable Days	487	291	196	182	80	186	190	173

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Suraksha Diagnostic Ltd FAQs

The current trading price of Suraksha Diagnostic on 17-Apr-2026 16:59 is ₹282.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Suraksha Diagnostic stood at ₹1,468.9 Cr

The latest P/E ratio of Suraksha Diagnostic as of 16-Apr-2026 is 41.54.

The latest P/B ratio of Suraksha Diagnostic as of 16-Apr-2026 is 6.06.

The 52-week high of Suraksha Diagnostic is ₹353.6 and the 52-week low is ₹224.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Suraksha Diagnostic is ₹286 ( Cr.) .

About Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited was incorporated as ‘Suraksha Diagnostic Private Limited’ as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata (RoC). Subsequently, the company was converted into a public limited company pursuant to a special resolution passed in the extra-ordinary general meeting of its Shareholders held on June 5, 2024, and consequently, the name of the company was changed to ‘Suraksha Diagnostic Limited’, and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre.

The company offers one-stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services through its operational network, consisting of its flagship central reference laboratory, 8 satellite laboratories (co-located with its diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. It generates revenue primarily through sales of its diagnostic services. It also provides vaccination services, and a broad spectrum of customized test packages, aimed at prediction/early detection of diseases.

In addition to integrated pathology and radiology testing services, it also offers omnichannel medical consultation services via online and offline modes to its customers. The doctors at its polyclinics range across specialties and super-specialties such as cardiology, pediatrics, dermatology, rheumatology, oncology, and nephrology. Its model of polyclinic chambers housed in diagnostic centres providing medical consultation services enables patient convenience through holistic integration of services and offering it the first right to a patient’s prescription leading to higher cross-selling opportunities to the company. It derives the majority of its revenues from the B2C segment.

Business area of the company

The company is primarily engaged in the business of running diagnostic centres for carrying out various pathological and radiological services.

Diagnostic services of the company

Routine pathology tests
Specialized pathology tests
Basic and intermediate radiology tests
Advanced radiology tests
Preventive and wellness services

Awards, accreditations, and recognition

2017: Best quality in service delivery awarded by ABP News.
2019: Best customer service in healthcare awarded by ABP News.
2021: Business Leader of the Year organised by World Leadership Congress & Awards and certificate of excellence at the Health Conclave 2021 organised by Zee24 Ghanta.
2022: Awarded the outstanding diagnostic chain of eastern Indian by ABP Ananda.
2023: Certificate of excellence in exemplary trust and commitment towards diagnostic services at the Health Conclave 2023 organised by Zee24 Ghanta.

History and milestones

2007: Launched the first centre of the Company at Kestopur, West Bengal.
2010: Launched centre at Khardah, West Bengal and number of operating centres increased to 5.
2013: Received first round of funding of Rs 300 million from private equity investor Lighthouse Funds, through their investment entity India 2020 Limited.
2016: Number of laboratories increased to 4 and number of operating centres increased to 25.
2016: Received second round of funding of Rs 200 million from OrbiMed Asia II Mauritius FDI Investments Limited (since amalgamated into OrbiMed Asia II Mauritius Limited), and also marked the exit of the India 2020 Limited from the Company.
2017: Acquired the business of Sunwell Diagnostic Private Limited for a consideration of Rs 30 million.
2019: Expansion of its operations to Meghalaya through a public-private partnership with the Government of Meghalaya.
2020: Acquisition of 2 pre-existing diagnostic centres in Kolkata from Future Medical and Research Trust for a consideration of Rs 67 million.
2023: Established its first 3T MRI and 128 CT at New Town.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Suraksha Diagnostic Ltd (SURAKSHA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Suraksha Diagnostic Share Price